Developing a population-based registry for patients with paraproteinemias or multiple myeloma

Journal of Clinical Epidemiology

Volumn 50, Issue 8, 1997, Pages 909-915

  Ong, F ^a,f   Hermans, J ^b   Noordijk, E M ^c   De Kieviet, W ^d,g   Wijermans, P W ^d   Seelen, P J ^e   Snijder, S ^a   Oostindier M J ^a   Kluin Nelemans, J C ^c  

^a Integraal Kankercentrum West   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d LEYENBURG HOSPITAL   (Netherlands)

^e MEDICAL CENTER HAAGLANDEN   (Netherlands)

^f NETHERLANDS CANCER INSTITUTE   (Netherlands)

^g ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

Author keywords

Monoclonal gammopathy of undetermined significance; Multiple myeloma; Paraproteins; Population based registry

Indexed keywords

PARAPROTEIN;

ADULT; AGED; ARTICLE; CANCER REGISTRY; DATA BASE; FEMALE; FOLLOW UP; HUMAN; INFORMATION PROCESSING; LABORATORY; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; MEDICAL PERSONNEL; MEDICAL RECORD; MULTIPLE MYELOMA; NETHERLANDS; PARAPROTEINEMIA; POPULATION RESEARCH; PRIORITY JOURNAL; SERUM;

DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MALE; MULTIPLE MYELOMA; NETHERLANDS; PARAPROTEINEMIAS; REGISTRIES;

EID: 0030815109     PISSN: 08954356     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-4356(97)00092-9     Document Type: Article

References (16)

1. Parkin DM, Sanghvi LD. Cancer registration in developing countries. In: Jensen OM, Parkin DM, MacLennan R, Muir CS, Skeet RG, Eds. Cancer Registration: Principles and Methods. IARC Scientific Publications No 95, Oxford, UK: Oxford University Press: 1991, pp. 185-207.
2. Otter R. Non-Hodgkin's Lymphoma in a population-based registry. Thesis, 1989.
3. Coebergh JWW, Oostindiër MJ, Tersmette AC, van Westering RP, Eds. Lustrumrapportage Regionale Kankerregistratie 1986-1990. Leiden, The Netherlands: Comprehensive Cancer Centre West; 1994.
4. Kyle RA. Plasma cell proliferative disorders. In: Hoffmann R, Benz EJ, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, Eds. Hematology: Basic Principles and Practice, 2nd edition. New York: Churchil Livingstone; 1995, pp. 1354-1375, 2nd ed.
5. Salmon SE, Cassady JR. Plasma cell neoplasms. In: DeVita VT Jr, Hellman S, Rosenberg SA, Eds. Cancer: Principles and Practice of Oncology. Philadelphia: Lippincott; 1989; 1853-1888.
6. Duggan DB, Schattner A. Unusual manifestations of monoclonal gammopathies: Autoimmune and idiopathic syndromes. Am J Med 1986; 81: 864-870.
7. Kyle RA, Lust JA. Monoclonal gammopathies of undetermined significance. Semin Haematol 1989; 26: 176.
8. Kyle RA. "Benign" monoclonal gammopathy - after 20 to 35 years of follow-up. Mayo Clin Proc 1993; 68: 26-36.
9. van de Poel MHW, Coebergh JWW, Hillen HFP. Malignant transformation of monoclonal gammopathy of undetermined significance among out-patients of a community hospital in Southeastern Netherlands. Br J Haematol 1995; 91: 121-125.
10. Lymphoma Tumor Group. Plasma cell disorders. In: Cancer Treatment Policies. Vancouver, B.C., Canada: British Columbia Cancer Agency; 1992: 4-6.
11. Durie BMG, Salmon SE. A clinical staging system for myeloma: Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975; 36: 842-854.
12. Visser O, Coebergh JWW, Schouten LJ, Eds. Incidence of Cancer in The Netherlands 1992. Utrecht, The Netherlands: SIG Health Care Information; 1995.
13. Durie BGM. Staging and kinetics of multiple myeloma. Semin Oncol 1986; 13: 300-309.
14. Axelsson U, Bachmann R, Hällén J. Frequency of pathological proteins (M-components) in 6,995 sera from an adult population. Acta Med Scand 1966; 179: 235-237.
15. Kyle RA, Finkelstein S, Elveback LR, Kurland LT. Incidence of monoclonal proteins in a Minnesota community with a cluster of multiple myeloma. Blood 1972; 40: 719-724.
16. Saleun JP, Vicariot M, Deroff P, Morin JF. Monoclonal gammopathies in the adult population of Finistère, France. J Clin Pathol 1982; 35: 63-68.